Paradigm Biocapital Advisors LP Edgewise Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,493,929 shares of EWTX stock, worth $122 Million. This represents 4.58% of its overall portfolio holdings.
Number of Shares
4,493,929
Previous 2,789,172
61.12%
Holding current value
$122 Million
Previous $74.4 Million
61.18%
% of portfolio
4.58%
Previous 2.68%
Shares
4 transactions
Others Institutions Holding EWTX
# of Institutions
215Shares Held
98.3MCall Options Held
885KPut Options Held
232K-
Orbimed Advisors LLC San Diego, CA15MShares$407 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$241 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$167 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$163 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$136 Million10.85% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.71B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...